Veraxa Biotech Holding AG (VRXA) Accumulated Expenses (2024 - 2025)
Veraxa Biotech Holding AG's (VRXA) quarterly Accumulated Expenses came in at $3.3 million in Q4 2025, up 62.71% year-on-year from $2.1 million in Q4 2024, and up 62.71% on a QoQ basis from $2.1 million in Q4 2024.
Veraxa Biotech Holding AG (VRXA) Accumulated Expenses (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXA) has 2 years of Accumulated Expenses data on file, last reported at $3.3 million in Q4 2025.
- On a quarterly basis, Accumulated Expenses rose 62.71% year-over-year to $3.3 million in Q4 2025; TTM through Dec 2025 was $3.3 million, a 62.71% increase from a year earlier, with the FY2025 full-year figure at $3.3 million, up 62.71% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $3.3 million, up from $2.1 million in the prior quarter.
- Over the last five years, Accumulated Expenses for VRXA reached as high as $3.3 million in Q4 2025 and fell as low as $2.1 million in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.35 Mn |
| Dec 31, 2024 | 2.06 Mn |